Clinical Trials

Jack Patterson examines how new off-the-shelf CAR T-cell therapy and optimized monoclonal antibodies could disrupt the multiple sclerosis treatment paradigm.

Alpheus Medical's new clinical trial tackles butterfly glioblastoma, leveraging non-invasive ultrasound and strategic financing to disrupt oncology.

Ahead of a critical 2027 data readout, Moleculin pitches a breakthrough leukemia drug while navigating a precarious financial runway.

AmyriAD Therapeutics is betting an all-stock deal can turn a missed Phase 2b endpoint into a breakthrough for cognitive impairment in schizophrenia.

GC Cell and QuantHealth are deploying predictive AI to simulate clinical trials, aiming to de-risk development and protect capital in cell therapy.

With a newly published pediatric case study and a recent $50 million funding lifeline, Quoin Pharmaceuticals is racing to deliver the first approved therapy for Netherton Syndrome.

Margaret Mitchell explores how a German biotech's moss-grown protein could shift the paradigm in complement-mediated diseases from inhibition to restoration.

Vaxcyte is arming itself with $1 billion in fresh capital to challenge Pfizer and Merck, leveraging a dual-tranche financing strategy to scale manufacturing.

Equillium's Phase 1 trial of EQ504 in Australia signals a strategic shift in ulcerative colitis care, prioritizing targeted mucosal healing.

With Phase 3 enrollment complete, vTv Therapeutics aims to succeed where pharmaceutical giants failed in the quest for a Type 1 diabetes pill.

HoneyNaps is transforming clinical trials by turning its FDA-cleared AI diagnostic software into a specialized Contract Research Organization for sleep data.

As GLP-1 drugs face scrutiny for causing lean tissue loss, advanced MRI biomarkers are reshaping clinical trials and the future of metabolic medicine.

Pliant Therapeutics taps veteran oncologist Dr. David Raben as CMO to steer its targeted ICI-refractory cancer program toward crucial 2027 clinical milestones.

Quorum Innovations has published early human data on Qi601, a postbiotic designed to trap microplastics in the gut before they enter human cells.

NuCana's new European patent for its cancer drug NUC-7738 strengthens its global IP moat, backing its clinical push against PD-1 resistant melanoma into 2029.

With a former FDA director at the helm, Keyron is positioning its reversible metabolic implant to disrupt the massive, drug-dominated weight-loss market.

Invivyd's VYD2311 beats mRNA vaccines on tolerability and boosts immunity, but regulatory and economic hurdles loom large for the novel therapy.

A Chinese hospital claims to functionally cure Type 1 diabetes. But are they selling a medical breakthrough or monetizing a physiological illusion?

As BioAge prepares for major investor conferences, the biotech firm is nearing a critical Phase 2 readout that could redefine cardiometabolic and obesity care.

As federal research stalls, a coalition of tech and finance veterans is injecting $15 million into a nimble clinical network targeting the biological roots of Long COVID and chronic Lyme disease.